Amneal Pharmaceuticals, Inc. (AMRX): R&D Expense
$186.18M
Year ended 2025-12-31
$175.57M
Trailing 12 months to 2026-06-30
-1.6%
3-year compound annual growth
+0.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $186.18M | -2.4% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $190.71M | +16.3% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $163.95M | -16.2% | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | $195.69M | -3.1% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $201.85M | +12.2% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $179.93M | -4.3% | 2023-03-03, From 2020-01-01 |
| 2019-12-31 | $188.05M | -3.2% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $194.19M | +13.3% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $171.42M | -4.2% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $179.02M | n/a | 2019-03-01, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $186.18M | -2.4% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $550.00M | +14.3% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $921.93M | +23.4% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $1.32B | +17.2% |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $452.00M | n/m |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $1.52B | +89.2% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $95.40M | -15.0% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $782.74M | -11.5% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $368.00M | +7.0% |
Compare AMRX, UTHR, BMRN, ALNY side by side · Screen every company in Pharmaceutical Preparations ↗